icad inc (ICAD) - Cash Flow Conversion Efficiency

Latest as of March 2025: 0.002x

Based on the latest financial reports, icad inc (ICAD) has a cash flow conversion efficiency ratio of 0.002x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($60.00K) by net assets ($30.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ICAD cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

icad inc - Cash Flow Conversion Efficiency Trend (1988–2024)

This chart illustrates how icad inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

icad inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of icad inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Atlas Lithium Corporation Common Stock
NASDAQ:ATLX
-0.202x
Whanin Pharm
KO:016580
0.006x
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
0.079x
Bogota Financial Corp
NASDAQ:BSBK
0.002x
Havila Kystruten AS
OL:HKY
-0.034x
Lhyfe SA
PA:LHYFE
-0.190x
Spyrosoft Spólka Akcyjna
F:2NP
0.126x
Peter Warren Automotive Holdings Ltd
AU:PWR
0.106x

Annual Cash Flow Conversion Efficiency for icad inc (1988–2024)

The table below shows the annual cash flow conversion efficiency of icad inc from 1988 to 2024. For the full company profile with market capitalisation and key ratios, see icad inc market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $28.68 Million $-3.94 Million -0.138x +7.41%
2023-12-31 $33.42 Million $-4.96 Million -0.149x +59.46%
2022-12-31 $34.90 Million $-12.79 Million -0.366x -81.18%
2021-12-31 $46.52 Million $-9.41 Million -0.202x +11.62%
2020-12-31 $30.52 Million $-6.99 Million -0.229x +83.67%
2019-12-31 $5.07 Million $-7.11 Million -1.401x -149.93%
2018-12-31 $6.90 Million $-3.87 Million -0.561x -9.11%
2017-12-31 $14.28 Million $-7.34 Million -0.514x -134.90%
2016-12-31 $25.04 Million $-5.48 Million -0.219x -277.07%
2015-12-31 $32.75 Million $-1.90 Million -0.058x -213.69%
2014-12-31 $62.78 Million $3.20 Million 0.051x +176.62%
2013-12-31 $21.38 Million $-1.42 Million -0.067x +56.16%
2012-12-31 $27.66 Million $-4.20 Million -0.152x +45.98%
2011-12-31 $36.05 Million $-10.14 Million -0.281x -10032.78%
2010-12-31 $73.21 Million $207.33K 0.003x -94.55%
2009-12-31 $66.31 Million $3.44 Million 0.052x -64.80%
2008-12-31 $66.29 Million $9.78 Million 0.147x +1153.97%
2007-12-31 $48.85 Million $574.57K 0.012x +112.79%
2006-12-31 $47.97 Million $-4.41 Million -0.092x -273.93%
2005-12-31 $52.73 Million $-1.30 Million -0.025x +28.16%
2004-12-31 $56.97 Million $-1.95 Million -0.034x +64.87%
2003-12-31 $47.90 Million $-4.67 Million -0.097x +7.33%
2002-12-31 $21.46 Million $-2.26 Million -0.105x +84.43%
2001-12-31 $2.04 Million $-1.38 Million -0.675x -241.10%
2000-12-31 $2.90 Million $-574.33K -0.198x +40.63%
1999-12-31 $3.00 Million $-1.00 Million -0.333x +63.49%
1998-12-31 $2.30 Million $-2.10 Million -0.913x -172.19%
1997-12-31 $3.40 Million $4.30 Million 1.265x +618.53%
1996-12-31 $4.10 Million $-1.00 Million -0.244x -72.76%
1995-12-31 $8.50 Million $-1.20 Million -0.141x -374.29%
1994-12-31 $13.60 Million $700.00K 0.051x -85.38%
1993-12-31 $12.50 Million $4.40 Million 0.352x +396.71%
1992-12-31 $12.70 Million $900.00K 0.071x +216.22%
1991-12-31 $8.20 Million $-500.00K -0.061x +83.36%
1990-12-31 $13.10 Million $-4.80 Million -0.366x -131.81%
1988-12-31 $7.90 Million $9.10 Million 1.152x --

About icad inc

NASDAQ:ICAD USA Medical Devices
Market Cap
$106.31 Million
Market Cap Rank
#19063 Global
#4337 in USA
Share Price
$3.87
Change (1 day)
+3.75%
52-Week Range
$3.65 - $3.89
All Time High
$21.22
About

iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurat… Read more